The Future of Cancer Treatment (pan-cancer): A 3-in-1 Antibody Design
/in Immunotherapy, Not PCa related, Preclinical Research/by MaxNodularin-R Enhances Abiraterone’s Effectiveness Against Castration-Resistant Prostate Cancer In Vivo
/in Preclinical Research/by MaxPersonalized Treatment for Advanced Prostate Cancer: The Power of Multi-Tracer PET Imaging
/in Preclinical Research/by MaxCTT2274: A Potential Game-Changer for Metastatic Prostate Cancer Treatment…start hating the word “potential”
/in Preclinical Research/by MaxImmunotherapy (potential) Breakthrough: Turning Cold Tumors Hot, Prostate Cancer is the Perfect Candidate
/in Immunotherapy, Preclinical Research/by MaxAnother Potential Breakthrough: 3-in-1 Antibody Shows Promise
/in Immunotherapy, Not PCa related, Preclinical Research/by MaxHopefully a Breakthrough: CLSP-1025 Targets Common p53 Mutation, Paving New Path for Solid Tumor Immunotherapy
/in Immunotherapy, Not PCa related, Preclinical Research/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Newsletter 43/2026 October 25, 2026
- Phase 3 DASL-HiCaP: Darolutamide Reduces Metastasis Risk in High-Risk Prostate Cancer October 24, 2026
- UPDATE: PROTEUS Substudy Shows Improved Event-Free Survival With Perioperative Apalutamide October 24, 2026
- UPDATE: Bavdegalutamide Shows Stronger Activity in Prostate Cancers With Specific AR Mutations October 23, 2026